31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

Interstitial Lung Diseases (ILD): Clinical Spectrum & Classification

Interstitial lung disease (ILD)—also termed diffuse parenchymal lung disease (DPLD)—encompasses a heterogeneous group of more than 200 distinct pulmonary disorders characterized by varying degrees of chronic inflammation and progressive fibroblastic proliferation within the alveolar interstitium, alveolar epithelium, and capillary endothelium. This inflammatory and fibrotic remodeling impairs alveolar gas exchange, leading to progressive ventilatory restriction and hypoxemia.

Classification of Interstitial Lung Diseases

ILDs are systematically categorized into four major clinical groups:

1. ILDs of Known Cause:
   • Connective Tissue Disease-Associated ILD (CTD-ILD): Systemic sclerosis (scleroderma), rheumatoid arthritis, systemic lupus erythematosus, polymyositis/dermatomyositis, Sjögren syndrome.
   • Environmental / Occupational Pneumoconioses: Asbestosis (insulation, shipyard workers; lower lobe plaques and fibrosis), Silicosis (sandblasters, quarry workers; upper lobe nodules with eggshell hilar calcification), Berylliosis (aerospace, nuclear workers).
   • Drug-Induced ILD: Amiodarone, bleomycin, methotrexate, nitrofurantoin, busulfan, checkpoint inhibitors.
2. Idiopathic Interstitial Pneumonias (IIP):
   • Idiopathic Pulmonary Fibrosis (IPF): The prototype fibrotic lung disease (UIP histopathologic pattern).
   • Nonspecific Interstitial Pneumonia (NSIP): Common in non-smoking middle-aged females and CTD; responsive to corticosteroids.
   • Cryptogenic Organizing Pneumonia (COP): Intra-alveolar fibroblastic buds (Masson bodies); dramatic response to oral steroids.
3. Granulomatous ILD:
   • Sarcoidosis: Multisystem non-caseating granulomatous disease.
   • Hypersensitivity Pneumonitis (HP): Immunologic response to inhaled organic antigens.
4. Rare / Miscellaneous ILDs:
   • Lymphangioleiomyomatosis (LAM), Pulmonary Langerhans Cell Histiocytosis (PLCH), Eosinophilic pneumonia.

---

Idiopathic Pulmonary Fibrosis (IPF): Pathogenesis, Diagnosis & Antifibrotic Therapy

Idiopathic Pulmonary Fibrosis is a specific form of chronic, progressive, fibrosing interstitial pneumonia of unknown cause, occurring primarily in older adults, limited to the lungs, and characterized histopathologically and radiologically by the Usual Interstitial Pneumonia (UIP) pattern.

Epidemiology & Pathogenetic Mechanics

• Demographics: IPF is predominantly a disease of older males (male-to-female ratio ~2:1), rarely diagnosed before age 55 (peak incidence 65-75 years). Over 70% of affected patients have a substantial history of cigarette smoking (>20 pack-years).
• Pathogenesis: IPF is no longer considered an inflammatory disease. Rather, it is driven by repetitive micro-injuries to an aging, genetically susceptible alveolar epithelium (mutations in telomerase genes TERT and TERC, or surfactant proteins SFTPC, and MUC5B promoter polymorphism).
• Injured alveolar type II epithelial cells undergo premature senescence and apoptosis, releasing excessive pro-fibrotic mediators, predominantly Transforming Growth Factor-beta 1 (TGF-β1) and Platelet-Derived Growth Factor (PDGF).
• These cytokines stimulate the persistent activation and proliferation of fibroblasts into fibroblastic foci, driving unregulated deposition of dense collagenous extracellular matrix, irreversible architectural destruction, and microscopic subpleural cystic transformation (honeycombing).

                 PATHOGENETIC SEQUENCE OF IDIOPATHIC PULMONARY FIBROSIS

     Aging / Smoking / Genetic Susceptibility (MUC5B, TERT/TERC)
                                │
                                ▼
     Repetitive Alveolar Type II Epithelial Micro-injury
                                │
                                ▼
     Aberrant Wound Healing & Senescence (Failure of Re-epithelialization)
                                │
                                ▼
     Unregulated TGF-β1, PDGF & VEGF Release
                                │
                                ▼
     Myofibroblast Proliferation & Collagen Matrix Deposition (Fibroblastic Foci)
                                │
                                ▼
     Extensive Architectural Distortion, Traction Bronchiectasis & Honeycombing

Clinical Presentation & Physical Examination

• Symptoms: Insidious, slowly progressive exertional dyspnea developing over months to years, frequently accompanied by a persistent, dry, hacking, nonproductive cough that is refractory to antitussive agents. Constitutional symptoms (fever, weight loss) are distinctly absent.
• Physical Examination Findings:
  • Bilateral End-Inspiratory Fine Crackles ('Velcro Crackles'): Heard prominently at the lung bases posteriorly, persisting after coughing. Present in >85% of patients at diagnosis; auscultation sounds remarkably like separating two strips of Velcro fasteners.
  • Digital Clubbing: Focal enlargement of the terminal phalanges with loss of the normal Lovibond angle (>180°) between the nail bed and nail plate; present in 30% to 50% of patients.
  • Signs of Cor Pulmonale (Late Disease): Accentuated pulmonic component of S2 (P2), elevated jugular venous pressure, right ventricular heave, tricuspid regurgitation murmur, and dependent peripheral edema indicate secondary pulmonary hypertension.

Diagnostic Evaluation: HRCT and Pulmonary Function Testing

1. High-Resolution CT (HRCT) of the Chest: The UIP Pattern

Thin-slice (≤1.5 mm) non-contrast chest CT with volumetric inspiratory and expiratory images is the definitive imaging examination. The Definite Usual Interstitial Pneumonia (UIP) pattern is characterized by four cardinal criteria:

1. Subpleural and Basal Predominance: Changes are maximal immediately adjacent to the visceral pleura and at the lung bases, sparing the apex.
2. Reticular Abnormalities: Thickened intralobular and interlobular septa producing a coarse net-like appearance.
3. Traction Bronchiectasis and Bronchiolectasis: Irregular, non-tapering dilation of bronchi and bronchioles dragged open by the elastic recoil of surrounding contracted fibrotic tissue.
4. Honeycombing: Clustered, subpleural, thick-walled (1-3 mm), cystic airspaces ranging from 3 to 10 mm in diameter, typically arranged in multiple contiguous layers immediately beneath the pleural surface.

• High-Yield Board Pearl: The presence of definite honeycombing on HRCT in a patient with a compatible clinical presentation is diagnostic of IPF and eliminates the need for invasive surgical lung biopsy.

2. Pulmonary Function Tests (PFTs): Restrictive Physiology

• Spirometry & Lung Volumes:
  • Forced Vital Capacity (FVC): Markedly reduced (<80% of predicted).
  • Forced Expiratory Volume in 1 second (FEV1): Proportionately reduced.
  • FEV1/FVC Ratio: Normal or elevated (typically >0.70 to 0.85) due to increased lung radial traction that keeps airways open during expiration.
  • Total Lung Capacity (TLC): Confirms true restriction when reduced to <80% of predicted.
• Diffusing Capacity of the Lung for Carbon Monoxide (DLCO):
  • Markedly and disproportionately reduced (<80% predicted, often <50%), reflecting the loss of functional alveolar-capillary membrane surface area and microvascular destruction.
  • Severe desaturation during the 6-minute walk test (6MWT; SpO2 falling below 88%) is a powerful independent predictor of mortality.

Evidence-Based Management of IPF

                  IPF PHARMACOTHERAPY & MANAGEMENT SUMMARY

     CONFIRMED IPF DIAGNOSIS (UIP Pattern on HRCT, Excluded Secondary Causes)
                                │
            ┌───────────────────┴───────────────────┐
            ▼                                       ▼
   ANTIFIBROTIC PHARMACOTHERAPY           COMPREHENSIVE SUPPORTIVE CARE
   • Nintedanib 150 mg PO BID             • Early Lung Transplant Referral
     (Tyrosine Kinase Inhibitor;            (Median survival 3-5 years)
      Adverse: Diarrhea, LFT elevation)   • Supplemental O2 if SpO2 <=88%
   • Pirfenidone 801 mg PO TID            • Pulmonary Rehabilitation
     (TGF-beta Inhibitor;                 • Influenza, Pneumococcal, COVID-19
      Adverse: Photosensitivity, Nausea)    Vaccinations
                                          • STRICTLY AVOID IMMUNOSUPPRESSION
                                            (Prednisone/Azathioprine Harmful!)

• The Immunosuppression Caution (The PANTHER-IPF Trial): Historically, clinicians treated IPF with systemic steroids and azathioprine. The landmark NIH-sponsored PANTHER trial (2012) demonstrated that the combination of prednisone + azathioprine + N-acetylcysteine resulted in significantly increased mortality and hospitalizations compared to placebo. Systemic corticosteroids and traditional immunosuppressants are strictly contraindicated in IPF!
• FDA-Approved Antifibrotic Agents:
  1. Nintedanib (OFEV): An intracellular small-molecule tyrosine kinase inhibitor targeting platelet-derived growth factor receptor (PDGFR), fibroblast growth factor receptor (FGFR), and vascular endothelial growth factor receptor (VEGFR). Dosed at 150 mg PO twice daily with food.
     • Adverse Effects: Diarrhea (occurs in >60% of patients; managed with loperamide and dose reduction to 100 mg BID) and hepatotoxicity (requires monthly liver function test monitoring for the first 3 months, then quarterly).
  2. Pirfenidone (Esbriet): An oral synthetic pyridone compound that exerts antifibrotic, anti-inflammatory, and antioxidant effects by directly downregulating TGF-β1 and collagen synthesis. Titrated over 3 weeks to a maintenance dose of 801 mg PO three times daily with meals.
     • Adverse Effects: Severe photosensitivity rash (mandates strict daily use of broad-spectrum SPF 50+ sunscreen and protective clothing), nausea, dyspepsia, anorexia, and elevated hepatic transaminases.
  • Therapeutic Impact: Both pirfenidone and nintedanib reduce the annual rate of FVC decline by approximately 50% (~100-120 mL/year preserved) and reduce acute exacerbation risk, but neither reverses existing fibrosis.
• Definitive Therapy: Lung Transplantation:
  • IPF carries a grim prognosis with a median survival of only 3 to 5 years from diagnosis without transplantation.
  • All eligible patients should be referred for lung transplant evaluation at the time of initial diagnosis, regardless of whether their PFTs appear mildly impaired.

---

Hypersensitivity Pneumonitis (Extrinsic Allergic Alveolitis)

Hypersensitivity pneumonitis (HP) is an immunologically mediated inflammatory and fibrotic lung disease resulting from repeated inhalation of specific environmental organic antigens or low-molecular-weight chemical haptens in sensitized individuals.

Classic Etiologies and Antigens

• Bird Fancier's / Pigeon Breeder's Lung: Inhalation of avian proteins (shed antigens from bird droppings, bloom on feathers, parakeets, pigeons, ducks, down bedding/comforters).
• Farmer's Lung: Inhalation of thermophilic actinomycetes (Saccharopolyspora rectivirgula, Thermoactinomyces vulgaris) colonizing moldy hay, straw, or grain stored at high humidity.
• Humidifier / Hot Tub Lung: Aerosolized non-tuberculous mycobacteria (Mycobacterium avium complex) or molds from contaminated residential ultrasonic humidifiers, hot tubs, or heating/ventilation systems.

Immunopathology & Diagnostic Distinctions

• Pathogenesis: Combined Type III (immune complex / IgG-mediated) and Type IV (delayed-type / cell-mediated Th1 and Th17) hypersensitivity reactions leading to lymphocytic infiltration of the alveolar walls and interstitial non-necrotizing, poorly formed granulomas.
• Clinical Presentation:
  • Non-Fibrotic (Acute/Subacute) HP: Episodes of fever, chills, dyspnea, dry cough, and malaise developing 4 to 8 hours following heavy antigen exposure, spontaneously resolving within 24 to 48 hours upon cessation of exposure.
  • Fibrotic (Chronic) HP: Insidious exertional dyspnea, fatigue, weight loss, and digital clubbing, mimicking IPF.
• Diagnostic Findings:
  • HRCT: Characterized by an upper- and mid-lung predominance (sparing the extreme lung bases), diffuse centrilobular ground-glass opacities, poorly defined centrilobular nodules, and mosaic attenuation due to expiratory air trapping. The combination of ground-glass, normal lung, and air-trapping produces the classic 'three-density pattern' (headcheese sign).
  • Bronchoalveolar Lavage (BAL): Demonstrates marked lymphocytosis (typically >50% lymphocytes) with a decreased CD4:CD8 T-cell ratio (<1.0).
• Management: The single most effective and disease-arresting intervention is complete antigen avoidance (removing birds, discarding down comforters, remediating water damage). For acute severe exacerbations, a tapering course of oral prednisone (0.5-1 mg/kg/day over 4 to 8 weeks) accelerates functional recovery.

---

Sarcoidosis: Clinical Presentation, Staging & Management

Sarcoidosis is a systemic inflammatory disease of unknown etiology characterized pathologically by the accumulation of well-formed, non-caseating (non-necrotizing) epithelioid granulomas in affected tissues, with pulmonary and intrathoracic lymph node involvement occurring in >90% of patients.

Epidemiology & Pathogenesis

• Demographics: Highest prevalence in the United States occurs among Black Americans (incidence 3 to 4 times higher than white individuals, with a lifetime risk of ~2.4%), who often experience more severe, progressive, and extrapulmonary disease. A second peak occurs in individuals of Scandinavian descent. Peak incidence is between 20 and 40 years of age, with a slight female predominance.
• Immunopathogenesis: Genetically predisposed hosts (HLA-DRB1 variants) mount an exaggerated antigen-driven Th1-polarized cellular immune response to an unknown environmental trigger. Activated CD4+ T-helper cells and alveolar macrophages release interferon-gamma (IFN-γ), interleukin-2 (IL-2), and TNF-alpha, orchestrating the aggregation of epithelioid histiocytes and multinucleated Langhans giant cells surrounded by a rim of CD4+ T lymphocytes into compact, non-caseating granulomas.

Chest Radiographic Staging (Scadding Criteria)

Thoracic sarcoidosis is classified into five radiographic stages, which correlate strongly with clinical prognosis:

---

Extrapulmonary Manifestations & Classical Eponyms

Sarcoidosis can affect virtually any organ system, creating diverse clinical presentations:

                      KEY EPONYMIC SYNDROMES IN SARCOIDOSIS

     ┌───────────────────────────────────────────────────────────┐
     │                     LÖFGREN SYNDROME                      │
     │  1. Erythema Nodosum (tender red shins)                   │
     │  2. Bilateral Hilar Lymphadenopathy on CXR                │
     │  3. Migratory Polyarthritis (bilateral symmetric ankles)  │
     │  • PROGNOSIS: >85% spontaneous remission within 1-2 years │
     │  • MANAGEMENT: Supportive (NSAIDs); BIOPSY NOT REQUIRED!  │
     └───────────────────────────────────────────────────────────┘

     ┌───────────────────────────────────────────────────────────┐
     │                    HEERFORDT SYNDROME                     │
     │                  (Uveoparotid Fever)                      │
     │  1. Anterior Uveitis                                      │
     │  2. Parotid Gland Enlargement (bilateral, painless)       │
     │  3. Facial Nerve Palsy (Lower Motor Neuron CN VII)        │
     │  4. Low-Grade Fever                                       │
     │  • MANAGEMENT: Systemic Oral Corticosteroids              │
     └───────────────────────────────────────────────────────────┘

1. Löfgren Syndrome (High-Yield Board Concept)

• An acute, benign presentation defined by the classic clinical triad:
  1. Erythema Nodosum: Painful, tender, erythematous-to-violaceous subcutaneous nodules on the anterior lower legs (shins).
  2. Bilateral Hilar Lymphadenopathy (BHL) on chest radiograph.
  3. Migratory Polyarthritis / Periarthritis: Most commonly involving both ankles symmetrically, often accompanied by marked periarticular swelling.
• Crucial Board Rule: Löfgren syndrome has a diagnostic specificity >95%. It runs a self-limiting course with >85% spontaneous remission within 12 to 24 months. Invasive tissue biopsy is strictly unnecessary, and systemic corticosteroids are avoided unless severe pain is unresponsive to oral NSAIDs.

2. Heerfordt Syndrome (Uveoparotid Fever)

• A rare acute subacute variant characterized by anterior uveitis, bilateral painless parotid gland tumefaction, peripheral facial nerve (CN VII) palsy, and low-grade pyrexia.

3. Organ-Specific Involvement

• Ocular Sarcoidosis (25-50%): Granulomatous anterior uveitis (blurred vision, eye pain, photophobia, ciliary flush, keratic precipitates) or posterior uveitis/retinal vasculitis. Every patient diagnosed with sarcoidosis must undergo a baseline ophthalmologic slit-lamp examination, because silent uveitis leads to posterior synechiae, secondary glaucoma, and blindness.
• Cutaneous Sarcoidosis (25%):
  • Erythema Nodosum: Indicates acute disease with good prognosis.
  • Lupus Pernio: Chronic, indurated, violaceous or purplish-red plaques and nodular lesions distributed across the nose, cheeks, lips, and ears. Pathognomonic for sarcoidosis; strongly correlates with chronic, refractory fibrotic pulmonary disease and upper respiratory tract granulomas.
• Cardiac Sarcoidosis (5% to 10% clinical, up to 25% autopsy): Granulomatous myocardial infiltration causing complete atrioventricular (AV) block, bundle branch blocks, ventricular tachycardia, congestive cardiomyopathy, and sudden cardiac death. Screen all patients with a 12-lead ECG. Confirmation requires cardiac MRI (demonstrating patchy late gadolinium enhancement) or 18F-fluorodeoxyglucose (FDG) cardiac PET. Primary prevention implantable cardioverter-defibrillator (ICD) placement is frequently required.
• Neurosarcoidosis (5%): Cranial mononeuropathies—particularly unilateral or bilateral lower motor neuron facial nerve (CN VII) palsy—are the most common manifestation, followed by basilar meningitis, sensory-motor neuropathy, and hypothalamic-pituitary granulomas causing diabetes insipidus or hyperprolactinemia.

---

Calcium Metabolism in Sarcoidosis: The 1-Alpha-Hydroxylase Mechanism

Abnormal calcium metabolism occurs in up to 30% of sarcoidosis patients (hypercalciuria is three times more frequent than hypercalcemia, causing nephrolithiasis and nephrocalcinosis):

               MECHANISM OF HYPERCALCEMIA IN SARCOIDOSIS

     Epithelioid Alveolar Macrophages within Granulomas
                                │
                                ▼
     CONSTITUTIVE EXPRESSION OF 1-ALPHA-HYDROXYLASE
     (Enzyme lacks feedback inhibition by Calcium or PTH)
                                │
                                ▼
     Excess Conversion: 25(OH)D3 ───> 1,25(OH)2D3 (Calcitriol)
                                            │
                                            ▼
     Increased Intestinal Calcium Absorption & Bone Resorption
                                            │
                                            ▼
     ─────────────────────────────────────────────────────────────
     LABORATORY PROFILE:
     • Serum Calcium: ELEVATED
     • Intact Parathyroid Hormone (PTH): SUPPRESSED (<10 pg/mL)
     • 25-Hydroxyvitamin D [25(OH)D]: NORMAL or LOW
     • 1,25-Dihydroxyvitamin D [1,25(OH)2D]: MARKEDLY ELEVATED
     • 24-Hour Urine Calcium: ELEVATED (>300 mg/24h)
     ─────────────────────────────────────────────────────────────

• Epithelioid histiocytes and activated macrophages within granulomas autonomously express 1-alpha-hydroxylase, which converts inactive 25-hydroxyvitamin D [calcidiol] to active 1,25-dihydroxyvitamin D [calcitriol].
• Unlike renal 1-alpha-hydroxylase, the macrophage enzyme is not regulated by parathyroid hormone (PTH) and lacks negative feedback inhibition by elevated calcium.
• Excessive calcitriol stimulates hyperabsorption of calcium in the small intestine and increases osteoclastic bone resorption, resulting in hypercalcemia with appropriately suppressed intact PTH.

---

Diagnostic Strategy & Stepwise Treatment of Sarcoidosis

Diagnostic Confirmation

Establishing the diagnosis of sarcoidosis requires three pillars:

1. A compatible clinical and radiographic presentation;
2. Histopathologic documentation of well-formed, non-caseating epithelioid cell granulomas in one or more organs;
3. Rigorous exclusion of alternative causes of granulomatous disease, particularly tuberculosis (acid-fast bacilli stain and mycobacterial culture), endemic fungi (Histoplasma, Coccidioides, Blastomyces via silver stains), and occupational exposures (berylliosis).

• Biopsy Strategy: Always biopsy the most accessible, minimally invasive abnormal tissue (e.g., cutaneous plaques or nodules, peripheral lymph nodes, conjunctiva). Do not biopsy erythema nodosum, as it shows non-specific septal panniculitis without granulomas. When superficial sites are absent, bronchoscopy with endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) of intrathoracic lymph nodes achieves diagnostic yields >90%.
• Serum ACE Level: Elevated in approximately 60% of patients due to synthesis by granuloma epithelioid cells; however, it has poor diagnostic sensitivity and specificity and is not used as a standalone diagnostic test.

Stepwise Treatment Algorithm

• Stage I Asymptomatic Sarcoidosis: NO TREATMENT. Observation with serial CXR and PFTs every 6 to 12 months, as >80% undergo spontaneous remission.
• Indications for Systemic Pharmacotherapy:
  • Debilitating or progressively worsening pulmonary symptoms with deteriorating PFTs (decline in FVC ≥10% or DLCO ≥15%);
  • Cardiac sarcoidosis (high risk of lethal arrhythmia);
  • Neurosarcoidosis;
  • Ocular sarcoidosis refractory to topical corticosteroid drops;
  • Persistent hypercalcemia or nephrocalcinosis;
  • Disfiguring cutaneous lesions (lupus pernio).
• First-Line Therapy: Systemic Oral Corticosteroids:
  • Prednisone 20 to 40 mg PO daily for 1 to 3 months, evaluating for symptomatic and radiographic response.
  • If clinical response is achieved, taper slowly over 6 to 12 months to a target maintenance dose of ≤5 to 10 mg daily, or discontinue.
• Second-Line (Steroid-Sparing) Immunosuppression:
  • Indicated for failure to respond to steroids, intolerable steroid toxicities (diabetes, severe osteoporosis, psychosis), or inability to taper prednisone below 10 mg daily.
  • Methotrexate (10 to 20 mg PO or SC once weekly) with daily folic acid (1 mg) is the preferred first-line steroid-sparing agent (monitor CBC, LFTs, and renal function).
  • Alternative second-line agents include azathioprine (1.5-2 mg/kg/day) or leflunomide.
• Third-Line Biologic Therapy:
  • TNF-alpha inhibitors, specifically Infliximab (monoclonal antibody against TNF-α; 3-5 mg/kg IV at weeks 0, 2, 6, then every 4-8 weeks) or Adalimumab.
  • Highly effective for refractory lupus pernio, severe neurosarcoidosis, and cardiac sarcoidosis resistant to conventional agents.